The Global Pancreatic Cancer Industry, projecting a valuation of approximately US$ 2,125.57 Million by the end of 2023. The study anticipates an extraordinary Compound Annual Growth Rate (CAGR) of 13.5%, laying the foundation for a significant leap to surpass US$ 7,541.09 Million by 2033.
Pancreatic cancer, a disease with profound implications, has emerged as one of the most prevalent forms of cancer worldwide. Alarming statistics reveal that it ranks as the seventh leading cause of cancer-related fatalities globally, underscoring the urgency of addressing this critical healthcare challenge.
The analysis further highlights a notable upward trend in the prevalence of pancreatic cancer, particularly in the Western world. Of concern is the rise in cases of pancreatic adenocarcinoma within developed regions. Lifestyle factors, including alcohol consumption and obesity, are believed to be substantial contributors to this worrisome trend.
Market Competition
Key players in the pancreatic cancer market are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics.
- In December 2022, scientists developed the world’s first early pancreatic cancer screening test, which utilizes worms to discover tumors. The test, which was initiated in Japan this month, claims to be 100% precise in detecting cancer and can trace it in its early stages.
- As per Oncolytics Biotech® Inc., the FDA approved pelareorep in December 2022 in conjunction with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab, the chemotherapeutic agent’s drugs gemcitabine, and nab-paclitaxel for the diagnosis of advanced or metastatic pancreatic ductal adenocarcinoma (TSX: ONC).
Global Pancreatic Cancer Industry: Segmentation
Valuable information covered in the FMI’s Pancreatic Cancer market report has been segregated into key segments and sub-segments.
By Treatment Type:
- Chemotherapy
- Immunotherapy
- Hormone Therapy
- Surgery
- Radiation Therapy
- Targeted Drug Therapy
- Others
By Cancer Type:
- Endocrine Pancreatic Cancer
- Exocrine Pancreatic Cancer
By End User:
- Hospitals
- Clinics
- Diagnostic Laboratories
- Research Institutes
- Research Laboratories
- Others
Global Pancreatic Cancer Industry: Competition Analysis
The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Global Pancreatic Cancer Industry. Competitive information detailed in the Pancreatic Cancer market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Global Pancreatic Cancer Industry report.
Key players covered in the report include:
- Pfizer Inc.
- Novartis AG
- Eli Lily and Company
- Bristol Myers Squibb Company
- Zydus Cadila
- Myriad Genetics Inc.
- F-Hoffmann-La Roche Ltd.
- PharmaCyte Biotech Inc.
- Teva Pharmaceutical Industries Ltd.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
